This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women

Sponsored by University of Texas at Austin

About this trial

Last updated 3 years ago

Study ID

00002778

Status

Completed

Type

Interventional

Phase

Phase 1

Placebo

Yes

Accepting

18 to 55 Years
Female

Trial Timing

Ended 3 years ago

What is this trial about?

Antidepressants have negative effects on genital arousal function that hinder quality of life and jeopardize medication adherence. Moderate sympathetic nervous system (SNS) activation through exercise has shown promising results for improving antidepressant-induced genital arousal dysfunction. It is feasible that caffeine - an SNS stimulant - could improve antidepressant-induced genital arousal difficulties if ingested prior to sex. The goal of the present pilot study is to examine whether the acute administration of 300mg of caffeine increases genital arousal in women experiencing antidepressant-induced genital arousal difficulties. Women will attend two counterbalanced sessions in which they ingest either 300mg caffeine or placebo. Fifteen minutes after ingestion, they will view an erotic film while their heart rate and genital sexual arousal are measured. Caffeine could serve as a low-cost, widely accessible intervention with minimal side effects if efficacy is shown.

What are the participation requirements?

Inclusion Criteria

* Between the of ages 18-55

* Fluent in English

* Experience antidepressant-induced arousal difficulties

* Experience regular menstrual periods (i.e., not perimenopausal or menopausal)

Exclusion Criteria

* A history or current diagnosis of panic attacks or panic disorder

* A history or current diagnosis of sexually transmitted disease(s)

* A history of major pelvic surgery that caused nerve damage

* Currently taking beta blockers, antipsychotics, anti-anxiolytics, hormonal contraceptives (unless the participant has been taking it for over 3 months), or any other medical treatment to enhance sexual response

* Other medical conditions or procedures that would preclude the participant's participation in the study (e.g., urinary tract infection, neurological impairment due to diabetes or stroke, or spinal cord damage)

* A history of childhood sexual abuse (CSA) that occurred prior to age 16